Post_template - Page 3 of 10

Genetic Engineering & Biotechnology News – Article

Our thanks to Genetic Engineering & Biotechnology News for featuring OncoOne’s CEO and Co-founder, Randolf Kerschbaumer, in an article highlighting the potential of multispecific antibody technologies, including our PreTargit® platform. Visit the link below to read the article and discover how we are developing our

BIO€QUITY, May 12-14, 2024, San Sebastian, ES

We are thrilled to announce that OncoOne’s CEO, Randolf Kerschbaumer, and CSO, Michael Thiele, will be present at BIOEQUITY24 in San Sebastian from May 12-14. Don’t miss the opportunity to schedule a meeting with them to explore our recent corporate progress and discuss the innovative

Labiotech.eu lists OncoOne as one of the 8 biotech companies to know in Austria!

Check out the recent article from Labiotech.eu that lists OncoOne as one of the 8 biotech companies to know in Austria! We are thrilled to be mentioned alongside other exciting companies and to be recognized for our work in generating novel immunotherapies, such as our

BIO-EUROPE Spring, March 18-20, 2024 Barcelona, ES

Attending BIO-EUROPE Spring? Schedule a one-to-one meeting with OncoOne’s CEO, Randolf Kerschbaumer, CSO, Michael Thiele, and VP of Preclinical and Translational R&D, Christine Landlinger-Schubert to learn more about recent and upcoming corporate milestones and to discuss partnering opportunities. Set up a meeting via the conference’s

OncoOne Announces Formation of Clinical Advisory Board to Support Development of ON104 for Chronic Inflammatory Diseases.

PDF Vienna, Austria – March 12, 2024 – OncoOne, a biotechnology company focused on discovering precision medicines for cancer and autoimmune diseases, announced today the formation of a clinical advisory board to provide strategic and clinical insights for the company’s lead program in immunology, ON104. ON104 is

Check out our brand-new oxMIF mechanism of action video

Our team at OncoOne is developing a pipeline of therapeutic antibodies capable of targeting Hashtag#oxMIF, the disease-related isoform of MIF discovered by our founders. Our mission is to leverage our breakthrough discovery and oxMIF’s potential as a target for systemic treatment of rheumatoid arthritis, nephritis,

Bio CEO & Investor Conference, February 26-27, 2024, New York, NY, US

OncoOne’s CEO, Randolf Kerschbaumer, heads to NYC for the BIOCEO24 on Feb 26-27. A key event for investors and biotech leaders, Randolf will discuss licencing and partnership opportunities for our oxMIF-targeting antibody assets, ON104 for inflammation and ON203 for immuno-oncology. OncoOne is also making strides

JP Morgan Conference, January 8-11, 2024, San Francisco, CA, US

Our CEO, Randolf Kerschbaumer, and CSO, Michael Thiele, are looking forward to connecting with the biotech, pharma, VC, and investor community at JP Morgan Healthcare Conference! Please feel free to reach out.

TRP 2023: Targeted Radiopharmaceuticals Summit, December 5-7, 2023, Berlin, DE

OncoOne invites you to join us at the Targeted Radiopharmaceuticals Summit Europe in Berlin from December 5 to 7. Our VP CMC Friedmund Bachmann will be sharing the latest insights on OncoOne’s innovative PreTarg-it® platform on Tuesday, December 6, 13:00 CET at TRP23. Explore how

PEGS 2023 Europe, October 13-16, 2023, Lisbon, PR

Join OncoOne at PEGS Europe in Lisbon from November 14 to 16. Our CTO Alexander Schinagl will be presenting the latest insights on OncoOne’s PreTarg-it® platform on Tuesday, November 14, at PEGS23. Discover how our Modular PreTargit Platform enhances RIT for challenging cancers, improving therapeutic